End of single drug therapy in sight, says Pharnext
This article was originally published in Scrip
Executive Summary
Having signed a validating first partnership deal with Ipsen, Pharnext hopes the pharmaceutical industry will feel more able to embrace the French start up's vision that the age of single drug therapy is over, chief executive Professor Daniel Cohen told Scrip.